Preliminary results of a multicenter randomized phase II trial of two different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)

Abstract

7124 Background: Cisplatin remains the cornerstone in the treatment of advanced NSCLC, but the optimal sequencing of drugs and the role of non-cisplatin doublets remains to be defined. The aim of t...